Ono Pharmaceutical Co Ltd
Ono Pharmaceutical's GHG Emissions Data Preview
In 2024, Ono Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Ono Pharmaceutical has also provided a category-level breakdown for 12 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
aVerified Sources Behind Ono Pharmaceutical’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Ono Pharmaceutical’s data sources below and access millions more through our Disclosure Search.
Insights into Ono Pharmaceutical's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of Ono Pharmaceutical amounted to 11,200 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Ono Pharmaceutical decreased by 30.86%, showing that the company has made progress in taking action to reduce the climate impact of its operations. a
Ono Pharmaceutical's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Ono Pharmaceutical's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Ono Pharmaceutical were 8,100 metric tons of CO₂ equivalent (tCO₂e). a
Has Ono Pharmaceutical reduced its Scope 1 emissions over time?
Since 2018, Ono Pharmaceutical's Scope 1 emissions have decreased by 14.74%, reflecting a declining long-term trend in Scope 1 emissions over time. a b
Compared to the previous year (2023), Ono Pharmaceutical's Scope 1 emissions increased by 20.9%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a
What are Ono Pharmaceutical's Scope 2 emissions?
In 2024, Ono Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 3,100 tCO₂e using the market-based method. a
Has Ono Pharmaceutical reduced its Scope 2 emissions over time?
Since 2018, Ono Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions ( Market-Based) have decreased by 83.77%, reflecting a declining long-term trend in Scope 2 emissions over time. a b
Compared to the previous year (2023), Ono Pharmaceutical's Scope 2 emissions (Market-Based) fell by 67.37% in 2024, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption. a
What methodology does Ono Pharmaceutical use for Scope 2 reporting?
In 2024, Ono Pharmaceutical reported its Scope 2 emissions using the market-based method. a
Ono Pharmaceutical's Scope 2 Emissions Over Time
- Total Scope 2 Market-Based
Insights into Ono Pharmaceutical's Value Chain Emissions
In 2024, Ono Pharmaceutical reported 34,100 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a
The 2024 disclosure of Ono Pharmaceutical includes a breakdown across 9 of the 15 Scope 3 categories defined by the GHG Protocol, down from 12 in 2023, indicating a decline in reporting granularity and reduced insight into the company's full value chain emissions. a
Ono Pharmaceutical's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Ono Pharmaceutical's Scope 3 emissions?
In 2024, Ono Pharmaceutical reported total Scope 3 emissions of 34,100 metric tons of CO₂ equivalent (tCO₂e). a
Approximately 99.41% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.59% came from downstream activities like product use, distribution, and end-of-life treatment. a
Has Ono Pharmaceutical reduced its Scope 3 emissions over time?
Since 2018, Ono Pharmaceutical's Scope 3 emissions have decreased by 58.52%, reflecting a declining long-term trend in Scope 3 emissions over time. a b
Compared to the previous year (2023), Ono Pharmaceutical's Scope 3 emissions decreased by 66.54%, highlighting the company's efforts to lower indirect emissions from its value chain. a
What categories of Scope 3 emissions does Ono Pharmaceutical disclose?
In 2024, Ono Pharmaceutical reported emissions for 9 out of the 15 Scope 3 categories defined by the GHG Protocol. a
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of Ono Pharmaceutical's Scope 3 emissions?
In 2024, the largest contributors to Ono Pharmaceutical's Scope 3 emissions were: a
- Capital Goods (Cat. 2): 22,800 tCO₂e (66.86%)
- Business Travel (Cat. 6): 4,800 tCO₂e (14.08%)
- Fuel- and Energy-Related Services (Cat. 3): 3,000 tCO₂e (8.8%)
Ono Pharmaceutical's Scope 3 Emissions by Categories
Insights into Ono Pharmaceutical’s GHG Emissions Intensity Compared to Industry Peers
In 2024, Ono Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 8,100 tCO₂e and total revenues of USD 3,319 millions. This translates into an emissions intensity of 2.44 tCO₂e per millions USD. a
Ono Pharmaceutical's Scope 1 Emissions Intensity Compared to Peers
How does Ono Pharmaceutical's GHG emissions intensity compare to its peers?
In 2024, Ono Pharmaceutical reported a Scope 1 emissions intensity of 2.44 tCO₂e per millions USD. Compared to the peer group median of 5.11 , this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors. a
Where does Ono Pharmaceutical rank on GHG emissions intensity within its industry?
In 2024, Ono Pharmaceutical ranked 8 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
Ono Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency. a
Insights into Ono Pharmaceutical's Total Carbon Footprint
In 2024, Ono Pharmaceutical reported a total carbon footprint of 45,300 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 61.64% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output. a
The largest contributor to Ono Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 75.28% of the company's total carbon footprint, followed by Scope 1 emissions at 17.88%. a